scholarly journals Positron emission tomography using F-18 fluorodeoxyglucose pre- and post-autologous stem cell transplant in non-Hodgkin's lymphoma

2008 ◽  
Vol 41 (11) ◽  
pp. 919-925 ◽  
Author(s):  
P B Johnston ◽  
G A Wiseman ◽  
I N M Micallef
Keyword(s):  
Positron Emission Tomography ◽  
Stem Cell ◽  
Hodgkin’S Lymphoma ◽  
Stem Cell Transplant ◽  
Autologous Stem Cell Transplant ◽  
Hodgkin's Lymphoma ◽  
Emission Tomography ◽  
Cell Transplant ◽  
Positron Emission ◽  
Non Hodgkin's Lymphoma

The Role of F18-fluorodeoxyglucose Positron Emission Tomography in the Management of Relapsed or Refractory Hodgkin’s Lymphoma

2012 ◽  
Vol 08 (02) ◽  
pp. 111
Author(s):  
Amanda F Cashen ◽  
Keyword(s):  
Positron Emission Tomography ◽  
Hodgkin’S Lymphoma ◽  
Response Assessment ◽  
Autologous Stem Cell Transplant ◽  
Hodgkin's Lymphoma ◽  
Emission Tomography ◽  
Cell Transplant ◽  
Prognostic Information ◽  
Positron Emission

Positron emission tomography (PET) is widely used in the diagnosis and response assessment after first-line treatment of Hodgkin’s lymphoma (HL). For the approximately 30 % of patients who relapse or have refractory disease, PET can provide valuable prognostic information during second-line therapy, at the time of autologous stem cell transplant (ASCT). Retrospective studies performed over the past decade have consistently found a significant association between a positive PET scan after salvage chemotherapy for HL and progression-free and overall survival after ASCT. In fact, the predictive value of pre-transplant PET appears higher than that of more traditional clinical risk factors. Unfortunately, there is little data to recommend the best treatment course for patients who have a positive pre-ASCT PET, and few studies have addressed the role of PET in other relapsed/refractory HL settings.

Sign in / Sign up

Export Citation Format

Share Document